CRP Flare–Response Predicts Efficacy of First-Line Anti–PD-1–Based Combination Therapy in Metastatic RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
C-reactive protein flare-response predicts long-term efficacy to first-line anti-PD-1-based combination therapy in metastatic renal cell carcinoma
Clin Transl Immunology 2021 Dec 01;[EPub Ahead of Print], N Klümper, P Schmucker, O Hahn, B Höh, A Mattigk, S Banek, J Ellinger, J Heinzelbecker, D Sikic, M Eckstein, A Strauß, F Zengerling, M Hölzel, P Zeuschner, C KalogirouFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.